Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

2 Jun 2016

Abstract excerpt

The role of genetic polymorphisms in cytochrome (CYP) 2D6 involved in the metabolism of 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) is unclear. Effects of genetic variants in CYP2D6 on the pharmacokinetics and pharmacodynamic effects of MDMA were characterized in 139 healthy individuals (70 men, 69 women) in a pooled analysis of eight double-blind, placebo-controlled crossover studies. In CYP2D6 poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cannabis and Cannabinoid Research
Share to Forensic Toxicology and Drug Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27253829
DOI: 10.1097/fpc.0000000000000231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individualsPMID 27253829Read ↗

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.Semantic proximity Read ↗

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?Semantic proximity Read ↗

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)Semantic proximity Read ↗

Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.Semantic proximity Read ↗

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.Semantic proximity Read ↗

In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone.Semantic proximity Read ↗

Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study.Semantic proximity Read ↗

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid AnalgesicsSemantic proximity Read ↗

Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.Semantic proximity Read ↗

Antidepressant Treatment and Altered CYP2D6 ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.